RxDoctor Payments Data

E Ezomo

Family · North Syracuse, NYNPI 1508103904

Payments from drug & device makers

$2,383in general payments, 2019–2025

Across 78 payments — averaging $30.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$433
  • Collegium Pharmaceutical, Inc.$256
  • Novo Nordisk$250
  • AbbVie$200
  • Nalu Medical, Inc.$159
  • Teva Pharmaceuticals USA, Inc.$155
  • plus $931 from 18 others

What the payments were for

  • Food & beverage$2,383100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,383 in reported general payments places this provider in the 85th percentile of 8,883 family providers in New York.

See all family providers in New York

Medicare billing

Part B allowed, 2024
$49,215
Medicare patients
244
Services billed
586

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Xtampza ErOxycodone Myristate22$10,166
OxycontinOxycodone Hcl13$6,636
Pregabalin142$6,007
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen381$5,975
Gabapentin319$4,094
Morphine Sulfate ErMorphine Sulfate158$3,658
Hydrocodone Bitartrate ErHydrocodone Bitartrate11$3,541
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen195$2,866
Tramadol Hcl ErTramadol Hcl31$2,364
Oxycodone Hcl157$1,762
Naloxone Hcl22$1,623
Fentanyl15$1,463
Cyclobenzaprine Hcl147$1,338
Tizanidine Hcl117$920
Amitriptyline Hcl67$918

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Xtampza Er$256$10,16622 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 8,883 family providers in New York.

Other family in North Syracuse

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →